The López-Belmonte family increase their interest in ROVI to 63.1%

The majority shareholders of Laboratorios Farmacéuticos Rovi, S.A. increase their interest in ROVI to 35,383,462 shares


The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in the company’s share capital to 63.107% through their investment vehicle Norbel Inversiones, S.L., which has thus become the direct holder of 35,383,462 of ROVI’s shares.

Juan López-Belmonte Encina said: This increase in the interest held by Norbel Inversiones, S.L. in ROVI’s share capital reflects the López-Belmonte family’s clear bet on the company and our confidence in ROVI’s business model and its future prospects”.

No votes yet
 
Related
Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due...
4 min
08/05/2024
Agreement to manufacture pre-filled syringes for a global pharmaceutical company Production will take place on one state-of-the-art...
3 min
25/04/2024
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024